Alemtuzumab and liver transplantation: A review

Shawn Dhesi, Brendon Boland, Steven D Colquhoun

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Liver transplantation has always been fraught with conflict. The ongoing shortage of organs for transplantation has led to sicker recipients and the pressure to utilize more marginal grafts. At the same time, increasing public scrutiny and regulatory oversight have emphasized lower costs and better outcomes. This environment exaggerates the importance of the most fundamental conflict: that between preventing allograft rejection and avoiding the toxicities of immunosuppressive agents and the risks of infection. Resolving this struggle requires skillful balancing and a need to keep abreast of the latest developments. Alemtuzumab is a still-new agent with relatively little clinical experience that, therefore, deserves a review and an update of current knowledge in the setting of liver transplantation. RECENT FINDINGS: The use of alemtuzumab in liver transplant recipients has shown promise with little information to support concerns over significantly increased risks of infectious complications. However, there have been very few studies overall and fewer still in the last 2-3 years. Much of what is known must still be extrapolated from experience in kidney transplant recipients. SUMMARY: Alemtuzumab appears to be a drug with significant potential advantages for liver transplant recipients. Improved renal function may be the largest potential advantage. However, the advantages may be offset in some groups. Defining subgroups will be critical to the definition of the optimal role of alemtuzumab in liver transplant recipients.

Original languageEnglish (US)
Pages (from-to)245-249
Number of pages5
JournalCurrent Opinion in Organ Transplantation
Volume14
Issue number3
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Liver Transplantation
Liver
Kidney
Organ Transplantation
Immunosuppressive Agents
Allografts
Transplants
Pressure
Costs and Cost Analysis
Transplant Recipients
alemtuzumab
Infection
Pharmaceutical Preparations

Keywords

  • Alemtuzumab
  • Campath 1H
  • Immunosuppression
  • Liver
  • Transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

Alemtuzumab and liver transplantation : A review. / Dhesi, Shawn; Boland, Brendon; Colquhoun, Steven D.

In: Current Opinion in Organ Transplantation, Vol. 14, No. 3, 01.06.2009, p. 245-249.

Research output: Contribution to journalReview article

Dhesi, Shawn ; Boland, Brendon ; Colquhoun, Steven D. / Alemtuzumab and liver transplantation : A review. In: Current Opinion in Organ Transplantation. 2009 ; Vol. 14, No. 3. pp. 245-249.
@article{ddc07b6ddba849c79830072054e0d3ec,
title = "Alemtuzumab and liver transplantation: A review",
abstract = "PURPOSE OF REVIEW: Liver transplantation has always been fraught with conflict. The ongoing shortage of organs for transplantation has led to sicker recipients and the pressure to utilize more marginal grafts. At the same time, increasing public scrutiny and regulatory oversight have emphasized lower costs and better outcomes. This environment exaggerates the importance of the most fundamental conflict: that between preventing allograft rejection and avoiding the toxicities of immunosuppressive agents and the risks of infection. Resolving this struggle requires skillful balancing and a need to keep abreast of the latest developments. Alemtuzumab is a still-new agent with relatively little clinical experience that, therefore, deserves a review and an update of current knowledge in the setting of liver transplantation. RECENT FINDINGS: The use of alemtuzumab in liver transplant recipients has shown promise with little information to support concerns over significantly increased risks of infectious complications. However, there have been very few studies overall and fewer still in the last 2-3 years. Much of what is known must still be extrapolated from experience in kidney transplant recipients. SUMMARY: Alemtuzumab appears to be a drug with significant potential advantages for liver transplant recipients. Improved renal function may be the largest potential advantage. However, the advantages may be offset in some groups. Defining subgroups will be critical to the definition of the optimal role of alemtuzumab in liver transplant recipients.",
keywords = "Alemtuzumab, Campath 1H, Immunosuppression, Liver, Transplantation",
author = "Shawn Dhesi and Brendon Boland and Colquhoun, {Steven D}",
year = "2009",
month = "6",
day = "1",
doi = "10.1097/MOT.0b013e32832b45d0",
language = "English (US)",
volume = "14",
pages = "245--249",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Alemtuzumab and liver transplantation

T2 - A review

AU - Dhesi, Shawn

AU - Boland, Brendon

AU - Colquhoun, Steven D

PY - 2009/6/1

Y1 - 2009/6/1

N2 - PURPOSE OF REVIEW: Liver transplantation has always been fraught with conflict. The ongoing shortage of organs for transplantation has led to sicker recipients and the pressure to utilize more marginal grafts. At the same time, increasing public scrutiny and regulatory oversight have emphasized lower costs and better outcomes. This environment exaggerates the importance of the most fundamental conflict: that between preventing allograft rejection and avoiding the toxicities of immunosuppressive agents and the risks of infection. Resolving this struggle requires skillful balancing and a need to keep abreast of the latest developments. Alemtuzumab is a still-new agent with relatively little clinical experience that, therefore, deserves a review and an update of current knowledge in the setting of liver transplantation. RECENT FINDINGS: The use of alemtuzumab in liver transplant recipients has shown promise with little information to support concerns over significantly increased risks of infectious complications. However, there have been very few studies overall and fewer still in the last 2-3 years. Much of what is known must still be extrapolated from experience in kidney transplant recipients. SUMMARY: Alemtuzumab appears to be a drug with significant potential advantages for liver transplant recipients. Improved renal function may be the largest potential advantage. However, the advantages may be offset in some groups. Defining subgroups will be critical to the definition of the optimal role of alemtuzumab in liver transplant recipients.

AB - PURPOSE OF REVIEW: Liver transplantation has always been fraught with conflict. The ongoing shortage of organs for transplantation has led to sicker recipients and the pressure to utilize more marginal grafts. At the same time, increasing public scrutiny and regulatory oversight have emphasized lower costs and better outcomes. This environment exaggerates the importance of the most fundamental conflict: that between preventing allograft rejection and avoiding the toxicities of immunosuppressive agents and the risks of infection. Resolving this struggle requires skillful balancing and a need to keep abreast of the latest developments. Alemtuzumab is a still-new agent with relatively little clinical experience that, therefore, deserves a review and an update of current knowledge in the setting of liver transplantation. RECENT FINDINGS: The use of alemtuzumab in liver transplant recipients has shown promise with little information to support concerns over significantly increased risks of infectious complications. However, there have been very few studies overall and fewer still in the last 2-3 years. Much of what is known must still be extrapolated from experience in kidney transplant recipients. SUMMARY: Alemtuzumab appears to be a drug with significant potential advantages for liver transplant recipients. Improved renal function may be the largest potential advantage. However, the advantages may be offset in some groups. Defining subgroups will be critical to the definition of the optimal role of alemtuzumab in liver transplant recipients.

KW - Alemtuzumab

KW - Campath 1H

KW - Immunosuppression

KW - Liver

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=67651049951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651049951&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e32832b45d0

DO - 10.1097/MOT.0b013e32832b45d0

M3 - Review article

C2 - 19417659

AN - SCOPUS:67651049951

VL - 14

SP - 245

EP - 249

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 3

ER -